中山醫學大學機構典藏 CSMUIR:Item 310902500/24230
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 17905/22920 (78%)
造訪人次 : 7511178      線上人數 : 504
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24230


    題名: The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis
    作者: Hsieh, PY;Hung, SC;Li, JR;Wang, SS;Yang, CK;Chen, CS;Lu, K;Cheng, CL;Chiu, KY
    關鍵詞: Metastasectomy;Metastatic renal cell carcinoma;Overall survival
    日期: 2021
    上傳時間: 2022-08-05T10:45:11Z (UTC)
    出版者: ELSEVIER SCIENCE INC
    ISSN: 1078-1439
    摘要: Purpose: Metastasectomy (MTS) is a treatment option for patients diagnosed with metastatic Renal Cell Carcinoma (mRCC). Nevertheless, the benefits of MTS as they pertain to survival remain controversial. This systematic review aims to compare the survival outcomes of patients who underwent MTS, as well as discover which clinical factors were related to the results. Methods: From their inception up to August 2020, a systematic review of the EMBASE, PubMed, Cochrane library, and Web of science databases was performed. Studies which reported outcomes on patients who underwent MTS for the treatment of mRCC were included. The sites, times, amount, histology types of metastasis, and prior nephrectomy were also analyzed. The primary efficacy end point was Overall Survival (OS). A meta-analysis was performed to calculate hazard ratio, 95% confidence intervals, and I2 values. Forest plots were constructed for each analysis group. Results: The systematic review and reference list search identified 294 articles, with 17 meeting studies as inclusion criteria. The MTS group showed a competitive advantage in OS, in that the non-MTS group was negatively associated with an overall survival rate (HR [nonMTS vs. MTS] = 2.15, 95% CI: 1.59-2.92, P< 0.001). Moreover, patients treated with the most recently available target therapy without MTS showed a significantly increased risk compared with the MTS group (HR = 1.82, 95% CI:1.23-2.70, P= 0.003). Additionally, metaanalysis revealed HR elevating in patients with nonlung only metastasis (HR = 1.87, 95% CI: 1.55-2.26, P< 0.001), synchronous metastasis (HR = 1.28, 95% CI: 1.10-1.49, P= 0.001), and multiple metastases (HR = 2.06, 95% CI: 1.64-2.59, P< 0.001). Clear-cell type mRCC (HR = 0.62, 95% CI: 0.48-0.82, P= 0.0006) and prior nephrectomy (HR = 0.37, 95% CI: 0.15-0.91, P= 0.03) were positively associated with a better overall survival rate. Conclusions: MTS is a treatment option for mRCC patients with prolonged overall survival time. The operation has additional advantages, particularly in patients with lung only metastasis, asynchronous metastasis, fewer metastasis sites, clear-cell type mRCC, and the patients who had received nephrectomy. (c) 2021 Elsevier Inc. All rights reserved.
    URI: http://dx.doi.org/10.1016/j.urolonc.2021.02.026
    https://www.webofscience.com/wos/woscc/full-record/WOS:000673072600006
    https://ir.csmu.edu.tw:8080/handle/310902500/24230
    關聯: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS ,2021 ,v39 ,issue7 ,p430-430
    顯示於類別:[中山醫學大學研究成果] 其他文獻

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML181檢視/開啟


    SFX Query

    在CSMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋